Deborah Falk
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Deborah Falk has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Chris J. Bushe
Eli Lilly and Company Ltd, Basingstoke, UK
1 shared publication - Elena Perrin
Eli Lilly, 13, Rue Pages, 92158 Suresnes Cedex, Paris, France
1 shared publication - Ernie Anand
Neuroscience Medical Affairs, Eli Lilly & Company Ltd, Windlesham, UK
1 shared publication - Holland C. Detke
Eli Lilly and Company, Indianapolis, IN, USA
1 shared publication - Marta Casillas
Eli Lilly and Company, Indianapolis, USA
1 shared publication - Rashna Chhabra-Khanna
Eli Lilly and Company, and/or one of its subsidiaries, Lilly Corporate Center, Indianapolis, IN, 46285, USA
1 shared publication
Latest Publications
- Open Access
- 2 April 2015
- Published by Springer Nature in BMC Psychiatry
- Vol. 15 (1) , 65
Olanzapine long-acting injection: a review of first experiences of post-injection delirium/sedation syndrome in routine clinical practice
Olanzapine long-acting injection (LAI) for the treatment of schizophrenia was associated with a cluster of symptoms termed post-injection delirium/sedation syndrome (PDSS) in a small percentage (~2%) of patients during clinical trials. The objective of this analysis was to evaluate the rate and clinical characteristics of PDSS since olanzapine LAI entered commercial use. Cases of PDSS were identified from all reported adverse events during worldwide commercial use of olanzapine LAI through to 1 March 2014. Data sources included two ongoing post-marketing safety studies as well as spontaneously reported adverse events from routine clinical practice over a 5-year period (1 March 2009 to 1 March 2014). A total of 338 PDSS events were identified. Of these, 91% occurred within 1 hour of injection, and 52% of these occurred within 15 minutes. None of the PDSS events in this analysis were fatal, and most resolved within 72 hours. The most common symptoms (occurring in >30% of cases) were sedation (61%), confusion (56%), dysarthria (54%), somnolence (46%), dizziness (45%) and disorientation (35%). Overall, PDSS occurred with approximately 0.07% of injections and in 0.46–1.03% of patients (reporting and incidence rates from spontaneous reports and post-marketing safety studies, respectively). The PDSS events reported during routine clinical use of olanzapine LAI are generally similar in incidence and presentation to those reported in clinical trials. Caution should be applied when interpreting spontaneously reported rates of adverse events, however, due to potential under-reporting. Implemented risk-minimisation activities may contribute substantially to the identification and appropriate management of patients with PDSS in clinical practice.
- 2 April 2015
- Published by Springer Nature in BMC Psychiatry
- Vol. 15 (1) , 65
Open AccessOlanzapine long-acting injection: a review of first experiences of post-injection delirium/sedation syndrome in routine clinical practice
Olanzapine long-acting injection (LAI) for the treatment of schizophrenia was associated with a cluster of symptoms termed post-injection delirium/sedation syndrome (PDSS) in a small percentage (~2%) of patients during clinical trials. The objective of this analysis was to evaluate the rate and clinical characteristics of PDSS since olanzapine LAI entered commercial use. Cases of PDSS were identified from all reported adverse events during worldwide commercial use of olanzapine LAI through to 1 March 2014. Data sources included two ongoing post-marketing safety studies as well as spontaneously reported adverse events from routine clinical practice over a 5-year period (1 March 2009 to 1 March 2014). A total of 338 PDSS events were identified. Of these, 91% occurred within 1 hour of injection, and 52% of these occurred within 15 minutes. None of the PDSS events in this analysis were fatal, and most resolved within 72 hours. The most common symptoms (occurring in >30% of cases) were sedation (61%), confusion (56%), dysarthria (54%), somnolence (46%), dizziness (45%) and disorientation (35%). Overall, PDSS occurred with approximately 0.07% of injections and in 0.46–1.03% of patients (reporting and incidence rates from spontaneous reports and post-marketing safety studies, respectively). The PDSS events reported during routine clinical use of olanzapine LAI are generally similar in incidence and presentation to those reported in clinical trials. Caution should be applied when interpreting spontaneously reported rates of adverse events, however, due to potential under-reporting. Implemented risk-minimisation activities may contribute substantially to the identification and appropriate management of patients with PDSS in clinical practice.